Chris Boulton is the founder of ProLynx. ProLynx has raised $70M in total funding. Latest round: Series A. Based in Emeryville, California.
Chris Boulton is the Chief Executive Officer of ProLynx, a biotechnology company developing ultra-long-acting medicines for obesity and metabolic conditions. He was appointed to the role in November 2025 after serving as the former global obesity marketing leader at Amgen. Boulton brings experience from Big Pharma to lead ProLynx's transition from stealth mode to advancing its clinical pipeline.
Full founder directory · Investor directory · Company funding database · Fundraising library